Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S-nitrosoglutathione reductase (GSNOR), also known as alcohol dehydrogenase class III or ADH5 in humans, is a highly conserved enzyme that plays a central role in the regulation of nitric oxide (NO) signaling by metabolizing S-nitrosoglutathione (GSNO), a major endogenous reservoir and carrier of NO bioactivity. GSNOR catalyzes the irreversible reduction of GSNO to oxidized glutathione (GSSG) and ammonia or hydroxylamine derivatives, thereby controlling intracellular levels of GSNO and indirectly regulating protein S-nitrosothiols (RSNOs). By modulating GSNO concentrations, GSNOR influences protein S-nitrosylation—a reversible post-translational modification where an NO group attaches to cysteine residues on proteins. This process affects diverse cellular functions such as metabolism, signal transduction, stress responses, immune function, smooth muscle relaxation, inflammation control, neuronal development, and cancer progression.
Inhibition of GSNOR leading to increased GSNO levels and altered protein S-nitrosylation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-nitrosoglutathione Reductase (GSNOR).